in Newswire March 3, 2020

Class Action Claims Patients Overpaid for Dementia-Treating Namenda IR Due to Drugmaker’s Anticompetitive ‘Scheme’

by Erin Shaak

Last Updated on March 3, 2020

A.F. of L. – A.G.C. Building Trades Welfare Plan v. Forest Laboratories, LLC

Filed: February 28, 2020 § 1:20-cv-01799

A proposed class action lawsuit alleges Forest Laboratories, LLC has engaged in an “anticompetitive scheme” through which the pharmaceutical company has been able to charge inflated prices for dementia drug Namenda IR.



New York

Last Updated on March 3, 2020 — 4:03 PM

Erin Shaak

Erin works primarily on’s newswire, reporting on cases as they happen.

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.